Home > Dermatology > AAD 2022 > AAD 2022 Highlights Podcast

AAD 2022 Highlights Podcast

Presented by
Dr Rachel Giles, Medicom
AAD 2022

In this episode (19:41 min), Medicom’s correspondent covers 6 presentations from the American Academy of Dermatology Annual Meeting (AAD 2022) which was held in Boston, MA, USA, 25-29 March 2022.

  1. Lebrikizumab improves skin lesions, pruritus, and quality of life in patients with AD
    Patients treated for moderate-to-severe atopic dermatitis (AD) benefitted significantly from therapy with the IL-13 blocker lebrikizumab. Efficacy improvements were not only seen in eczema measures but also in the reduction of sleep loss and itch.
  2. NO-releasing gel: a novel way to fight molluscum contagiosum
    A gel consisting of 2 components with a novel mode of action showed to be effective against molluscum contagiosum (MC). Almost a third of patients achieved complete clearance of all skin lesions after 12 weeks of treatment with the berdazimer 10.3% gel in the phase 3 B-SIMPLE 4 trial.
  3. Ruxolitinib cream demonstrates long-term efficacy in non-segmental vitiligo
    The 52-weeks results of the phase 3 TRuE-V1 and TRuE-V2 trials showed that most vitiligo patients can achieve substantial repigmentation with a cream containing the topical JAK1/JAK2 inhibitor ruxolitinib. The cream was well tolerated with no clinically significant application site reactions.
  4. Novel anticholinergic gel is highly effective in hyperhidrosis
    Topically applied sofpironium bromide gel proved to be effective and well tolerated in the phase 3 Cardigan 1 and Cardigan 2 trials including patients with primary axillary hyperhidrosis. Both subjective and objective parameters were improved with only mild anticholinergic side effects.
  5. Dupilumab for prurigo nodularis: a light at the end of the tunnel?
    A significantly higher proportion of prurigo nodularis patients treated with dupilumab achieved a clinically meaningful amelioration of itch and disease stage compared with placebo in the phase 3 LIBERTY-PN PRIME 2 trial. Safety assessments were in line with the known dupilumab profile.
  6. Apremilast: A new option for recalcitrant dermatomyositis?
    With an overall response rate of 87.5%, apremilast demonstrated efficacy as an add-on treatment for recalcitrant dermatomyositis without raising safety concerns. Downregulation of key signalling pathways was revealed through immunohistochemical and gene analysis.

Enjoy listening!

Copyright ©2022 Medicom Medical Publishers

Posted on